Insight

Jul 17, 2025, 08:12

Erdal Toprak: More Effective, Lower-Toxicity Combination Therapies for Acute Myeloid Leukemia

Erdal Toprak, Co-Founder of BAIT-Bio LLC, shared a post on LinkedIn:

“Our lab’s first cancer paper is now out! We systematically screened 105 clinically relevant drug pairs and quantified their interactions across six genetically diverse acute myeloid leukemia (AML) cell lines. We found that synergy and antagonism are prevalent but rarely conserved across different genetic backgrounds—an IDH2 mutation, for example, can flip a synergistic combination into an antagonistic one.

These genotype-specific insights can point the way toward more effective, lower-toxicity combination therapies. Read more.”

Title: Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines

Authors: Fatma Neslihan Kalkan, Muhammed Sadik Yildiz, N. Ezgi Wood, Michael Farid, Melissa McCoy, Milo M. Lin, Chengcheng Zhang, Bruce A. Posner, Stephen S. Chung, Erdal Toprak

Read the Full Article.

Erdal Toprak

Bruce A. Posner cancer Chengcheng Zhang Erdal Toprak Fatma Neslihan Kalkan Melissa McCoy Michael Farid Milo M. Lin Muhammed Sadik Yildiz N. Ezgi Wood OncoDaily Oncology Stephen S Chung

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders